PowerPoint Presentation Achievement of the National Psoriasis Foundation Treatment Treat-to-Target Goals in the US Ixekizumab Customer Support Program Key Eligibility Criteria ■ Patients with psoriasis enrolled in the US Ixekizumab CSP ■ ≥18 years of age ■ Commercial insurance ■ Initiated ixekizumab within 7 days of screening ■ Device with access to the internet Assessments ■ Web-based questionnaires administered at baseline, Weeks 2, 4, 8, 12, and 24 ■ Body Surface Area (BSA) measured by PREPI questionnaire – PREPI: Single question in which the patient estimates how many palms of the hand are needed to cover psoriasis patches on the body – A palm of the patient’s hand is ~ 1% BSA ■ Psoriatic arthritis diagnosis is self-reported Alice B. Gottlieb1, Russel Burge2, William N. Malatestinic2, Baojin Zhu2, Yunyang Zhao2, Julie McCormack3, Miriam Kimel3, Meghan Feely2, Joseph F. Merola4 1Icahn School of Medicine at Mount Sinai, New York, USA; 2Eli Lilly and Company, Indianapolis, USA; 3Evidera, Bethesda, USA; and 4Harvard Medical School, Brigham and Women’s Hospital, Boston, USA METHODS US Ixekizumab CSP Design Patient Demographics and Baseline Characteristics DISCLOSURES  A. B. Gottlieb has received honoraria as an advisory board member, non-promotional speaker or consultant for: Amgen, AnaptysBio, Avotres Therapeutics, Boehringer Ingelheim, Bristol Myers Squibb, Dice Therapeutics, Dermavant, Eli Lilly, Janssen, Novartis, Pfizer, Sanofi, Sun Pharma, UCB Pharma, and Xbiotech (stock options for an RA project); research/educational grants from: AnaptysBio, Janssen, Novartis, Ortho Dermatologics, Sun Pharma, BMS, and UCB Pharma; all funds go to the Icahn School of Medicine at Mount Sinai; R. Burge, W. N. Malatestinic, B. Zhu, Y. Zhao, M. Feely are shareholders and employees of: Eli Lilly and Company; M. Feely is a clinical instructor at: Mount Sinai Hospital and has received consulting, travel, or speaker fees from: Aerolase, Castle Biosciences, Galderma Aesthetics, Glow Recipe, La Roche-Posay - L'Oréal, Revian, Sonoma Pharmaceuticals, Sun Pharma, and Suneva Medical; J. McCormack and M. Kimel declare no conflicts of interest; J. F. Merola is a consultant and/or investigator for: AbbVie, Amgen, Biogen, Bristol Myers Squibb, Dermavant, Eli Lilly and Company, Janssen, LEO Pharma, Novartis, Pfizer, Sanofi Regeneron, Sun Pharma, and UCB Pharma  This study was sponsored by Eli Lilly and Company. Medical writing services were provided by Molly Tomlin, MS, MEd, of Eli Lilly and Company REFERENCES 1. Armstrong AW, et al. J Am Acad Dermatol. 2017;76(2):290-8 2. Armstrong A, et al. J Am Acad Dermatol. 2021; 85(2): 330-336 Target Response (N=422) Acceptable Response (N= 294) Age, mean ± SD 46.7 ± 12.1 46.1 ± 11.8 Women, n (%) 266 (63%) 179 (61%) Duration from onset of psoriasis, months, mean ± SD 193.8 ± 164.9 205.3 ± 165.9 Baseline BSA, mean ± SD 11.7 ± 16.3 15.8 ± 18.0 Psoriasis locations, n (%) Scalp psoriasis 276 (65%) 206 (70%) Genital psoriasis 105 (25%) 81 (28%) Nail psoriasis 116 (27%) 87 (30%) Psoriatic arthritis, n (%) 211 (50%) 144 (49%) Bio-experienced (previous 2 years), n (%) 178 (42%) 124 (42%) Study was sponsored by Eli Lilly and Company BACKGROUND ■ The National Psoriasis Foundation (NPF) has defined treatment goals to improve patient care in psoriasis1 – The goals establish targets to inform treatment decisions, reduce disease burden, and improve patient outcomes in clinical practice ■ The real-world effectiveness of ixekizumab, a highly selective IL- 17A monoclonal antibody, has been evaluated in patients with moderate-to-severe psoriasis in the Taltz Customer Support Program (CSP) OBJECTIVE ■ To evaluate the real-world effectiveness of patients initiating ixekizumab to achieve NPF-defined treat-to-target goals after 12 weeks of treatment with data from the CSP KEY RESULTS DISCUSSION  Although BSA was measured differently (patient vs. clinical assessment) the findings for target and acceptable responses in this real-world study were similar to those seen in the UNCOVER Phase III clinical trials2 − With a real-world study population, factors influencing outcomes may also include, but are not limited to, compliance with medications, and experience with biologics CONCLUSIONS ■ The results from this study provide evidence of the real- world effectiveness of ixekizumab; observations from the overall sample were similar to those across the subgroups, PsA and biologic use Winter Clinical Dermatology Conference (WCDC); Kohala Coast, USA; 13-18 January 2023 Percentage of patients achieving NPF target and acceptable response after 12 weeks of treatment Scan or click the QR code or use this URL (https://lillyscience.lilly.com/congress/wcdc2023) for a list of all Lilly content presented at the congress. Other company and product names are trademarks of their respective owners. ABBREVIATIONS BSA=body surface area; CSP=Customer Support Program; DLQI=Dermatology Life Quality Index; IXE=ixekizumab; NPF=National Psoriasis Foundation; NRS=numeric rating scale; PatGA=Patient’s Global Assessment; PREPI=Patient-Reported Extent of Psoriasis Involvement; PsA=psoriatic arthritis; PsO=psoriasis; SD=standard deviation NPF Treatment Goals1 ■ At 12 weeks after treatment initiation − Target response: BSA ≤1% − Acceptable response: BSA ≤3% or improvement in BSA ≥75% from baseline Statistical Analyses ■ Descriptive analyses with observed data ■ Inclusion in the study population – Target response: patients were required to have BSA >1% at baseline – Acceptable response: patients were required to have a baseline BSA >3% Percentage of patients achieving NPF target and acceptable response after 12 weeks of treatment by bio-experience Percentage of patients achieving NPF target and acceptable response after 12 weeks of treatment by psoriatic arthritis 0 10 20 30 40 50 60 70 80 90 100 75.0 55.0 R es po ns e (% ) Target Response (N=303) Acceptable Response (N=213) For target response, analyses included patients with a baseline BSA score >1 and non-missing BSA score at Week 12 For acceptable response, analyses included patients with a baseline BSA score >3 and non-missing BSA score at Week 12 0 10 20 30 40 50 60 70 80 90 100 73.0 77.0 57.0 52.0 R es po ns e (% ) Bio- Naive (N=167) Bio- Naive (N=120) Bio- Experienced (N=136) Bio- Experienced (N=93) Target Response Acceptable Response 0 10 20 30 40 50 60 70 80 90 100 75.0 75.0 54.0 56.0 R es po ns e (% ) With PsA (N=154) With PsA (N=106) PsO Only (N=149) PsO Only (N=107) Target Response Acceptable Response Slide Number 1